Pioneering a disruptive
therapeutic modality
Transformative medicines for
Targeted Protein Stabilization
Our Approach
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need. We are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.
The big idea
Targeting a shared mechanism driving disease – protein turnover
The challenge
123-456-7890
Drugging a universal degradation
signal in a target-specific manner
The solution
Find us on Facebook
Establishing an adaptable platform
for restoring protein stability
Reduced protein expression or aberrant protein turnover is a common underlying driver of disease. Genetic mutations can reduce the stability of proteins with essential function; tumor cells often eliminate key regulatory factors to grow unchecked; pathogens co-opt the host ubiquitin-proteasome system (UPS) to modulate immune response. Ubiquitin is a universal tag that marks proteins for destruction and has emerged as a highly sought-after therapeutic target. Although the therapeutic value of augmenting protein stabilization via the UPS has been demonstrated with proteasome inhibitors, these drugs globally inhibit protein degradation in a non-specific manner, limiting their use outside of oncology due to poor tolerability and highlighting the need for targeted approaches.
Our Platform
At Stablix, we are establishing a new paradigm for tackling diverse diseases by harnessing the power of the body’s own cellular machinery. Our RESTORED™ platform generates heterobifunctional small-molecules (RESTORACS™) that selectively recruit active deubiquitinases (DUBs) to target proteins to precisely remove ubiquitin and restore protein function. We are initially leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.
Who We Are
Stablix is a New York City-based preclinical stage biotechnology company, pioneering small molecule medicines for targeted protein stabilization. We are an experienced, multi-disciplinary team with a combined power of industry knowledge and creative talent.
Leadership
%20(1).png)
Tony Kingsley
CEO
Kevin Sprott, PhD
COO
Co-Founder
Eddine Saiah, PhD
CSO
Brian Bowman, PhD
SVP of Biology
Co-Founder
Scott Kanner, PhD
Associate Director
Platform Sciences
Co-Founder
Uddhav Shigdel, PhD
Director
Biomolecular Sciences
Yukie Takabatake, PhD
Associate Director
Cellular Biology
Scientific Advisors
Henry Colecraft, PhD
Chair of SAB
Co-Founder
Benedikt Kessler, PhD
University of Oxford
Professor
Chris Dinsmore, PhD
CSO Kronos Bio
Chris Roberts, PhD
Chief Executive Officer
Civetta Therapeutics
Stephen Hale, PhD
Independent Consultant
Andrew Turnbull, PhD
Senior Principal Scientist
CRUK-TDL
Huseyin Mehmet, PhD
Executive Director, New Ventures
UMass Medical School
Mark Saulnier, PhD
Former Research Fellow
Bristol-Myers Squibb
Megan Yao, PhD
Independent Consultant
Jue Chen
William E. Ford Professor Investigator, Howard Hughes Medical Institute; National Academy of Sciences
Board of Directors
Carlo Rizzuto, PhD
Director
Clare Ozawa, PhD
Director
Ali Behbahani, MD
Director
Tony Kingsley
Director
Douglas Williams, PhD
Director
J.C. Lopez, MD
Observer
Bihua Chen
Observer
Ezana Demissie
Observer
Our Investors
